Search

Displaying results 1031 - 1040 of 4591 in total
  1. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563] … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying

  2. Drug

    BHV-1300

    go.drugbank.com/drugs/DB22673
    Investigational

    BHV-1300 is a IgG1,2,4 selective degrader being investigated for the treatment of Grave's disease.

  3. Drug

    Isoprenaline

    go.drugbank.com/drugs/DB01064
    ApprovedInvestigational

    [A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline].

  4. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878] … [L50768] On June 10, 2024, elafibranor was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis (PBC).

  5. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.

  6. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.

  7. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. … It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.

  8. Drug

    Sucralfate

    go.drugbank.com/drugs/DB00364
    ApprovedInvestigational

    It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076]. … It is considered a _cytoprotective agent_, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among

  9. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Normiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.

  10. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.